Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Peritoneal Neoplasms

abstract

  • The recommended phase II dose of bortezomib administered in combination with carboplatin (AUC 5) is 1.3 mg/m2/dose.

publication date

  • December 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.16.006

PubMed ID

  • 16135465

Additional Document Info

start page

  • 5943

end page

  • 9

volume

  • 23

number

  • 25